These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 38244722)
1. Colistin versus polymyxin B for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Vieceli T; Henrique LR; Rech TH; Zavascki AP J Infect Chemother; 2024 Jul; 30(7):621-625. PubMed ID: 38244722 [TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of molecular characteristics, risk factors, and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Cheng Y; Cheng Q; Zhang R; Gao JY; Li W; Wang FK; He ZX; Sun QQ; Meng HB; Yu S BMC Microbiol; 2024 Aug; 24(1):309. PubMed ID: 39174950 [TBL] [Abstract][Full Text] [Related]
3. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection. Medeiros GS; Rigatto MH; Falci DR; Zavascki AP Int J Antimicrob Agents; 2019 Feb; 53(2):152-157. PubMed ID: 30722960 [TBL] [Abstract][Full Text] [Related]
4. Bloodstream Infections due to Carbapenem-Resistant Shen L; Lian C; Zhu B; Yao Y; Yang Q; Zhou J; Zhou H Microb Drug Resist; 2021 Feb; 27(2):227-233. PubMed ID: 32584202 [TBL] [Abstract][Full Text] [Related]
5. Combined effect of Polymyxin B and Tigecycline to overcome Heteroresistance in Carbapenem-Resistant Klebsiella pneumoniae. Tian Y; Zhang Q; Wen L; Chen J Microbiol Spectr; 2021 Oct; 9(2):e0015221. PubMed ID: 34704782 [TBL] [Abstract][Full Text] [Related]
6. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems. Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of short- versus prolonged-courses of antimicrobial therapy for carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A propensity score-matched cohort study. You TY; Lo CL; Tsai WC; Jan HE; Ko WC; Lee NY J Microbiol Immunol Infect; 2024 Aug; 57(4):594-600. PubMed ID: 38849216 [TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes and safety of polymyxin B versus tigecycline combination therapy for pneumonia of carbapenem-resistant Chen J; Xia B; Liu Y; Sun W; Liu F; Pang J; Cheng H Ann Med; 2024 Dec; 56(1):2397087. PubMed ID: 39239861 [TBL] [Abstract][Full Text] [Related]
9. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M; Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283 [TBL] [Abstract][Full Text] [Related]
10. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066 [TBL] [Abstract][Full Text] [Related]
11. Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections. Gomez-Simmonds A; Nelson B; Eiras DP; Loo A; Jenkins SG; Whittier S; Calfee DP; Satlin MJ; Kubin CJ; Furuya EY Antimicrob Agents Chemother; 2016 Jun; 60(6):3601-7. PubMed ID: 27044555 [TBL] [Abstract][Full Text] [Related]
12. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China. Chang H; Wei J; Zhou W; Yan X; Cao X; Zuo L; Chen S; Yao K; Huang R; Chen Y; Wu C J Infect Public Health; 2020 May; 13(5):784-790. PubMed ID: 31843651 [TBL] [Abstract][Full Text] [Related]
13. Clinical, biological and genome-wide comparison of carbapenem-resistant Klebsiella pneumoniae with susceptibility transformation to polymyxin B during therapy. Wang Y; Luo Q; Chen T; Chi X; Zhou Y; Fu H; Lu P; Xiong L; Xiao T; Zheng B; Shen P; Xiao Y Clin Microbiol Infect; 2023 Oct; 29(10):1336.e1-1336.e8. PubMed ID: 37423426 [TBL] [Abstract][Full Text] [Related]
14. Emergence of polymyxin B resistance in a polymyxin B-susceptible KPC-producing Klebsiella pneumoniae causing bloodstream infection in a neutropenic patient during polymyxin B therapy. Zavascki AP; Girardello R; Magagnin CM; Antochevis LC; Maciel RA; Palmeiro JK; Gales AC Diagn Microbiol Infect Dis; 2018 Feb; 90(2):134-138. PubMed ID: 29150371 [TBL] [Abstract][Full Text] [Related]
15. Epidemiology of carbapenem-resistant Wang Y; Lei H; Zhang Y; Yang Q; Wang Y; Wang J; Xu C; Yu J; Zhou L; Kang X; Cui L Antimicrob Resist Infect Control; 2018; 7():66. PubMed ID: 29942492 [TBL] [Abstract][Full Text] [Related]
16. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy. Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374 [TBL] [Abstract][Full Text] [Related]
17. Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia. Lee NY; Lo CL; Chen PL; Syue LS; Li CW; Li MC; Ko WC Int J Antimicrob Agents; 2021 Feb; 57(2):106250. PubMed ID: 33264671 [TBL] [Abstract][Full Text] [Related]